A Study to Assess the Long- Term Safety of TC-5214 as an Adjunct Therapy in Patients With Major Depressive Disorder

This study has been completed.
Sponsor:
Collaborator:
Targacept Inc.
Information provided by (Responsible Party):
AstraZeneca
ClinicalTrials.gov Identifier:
NCT01152554
First received: June 28, 2010
Last updated: March 14, 2014
Last verified: March 2014

June 28, 2010
March 14, 2014
June 2010
February 2012   (final data collection date for primary outcome measure)
  • Frequency of Patients Experiencing at Least One Adverse Event (AE) [ Time Frame: Randomization (Week 0) to end of the follow-up period (Week 54) ] [ Designated as safety issue: No ]
    The frequency of patients experiencing at least one AE during the randomized treatment or follow-up periods was calculated.
  • Frequency of Patients Experiencing AEs That Resulted in Discontinuation of Investigational Product (IP) [ Time Frame: Randomization (Week 0) to end of the follow-up period (Week 54) ] [ Designated as safety issue: No ]
    The frequency of patients experiencing AEs that resulted in discontinuation of IP during the randomized treatment or follow-up periods was calculated.
  • Frequency of Patients Experiencing Serious Adverse Events (SAEs) [ Time Frame: Randomization (Week 0) to end of the follow-up period (Week 54) ] [ Designated as safety issue: No ]
    The frequency of patients experiencing serious adverse events (SAEs) during the randomized treatment or follow-up periods was calculated.
AEs, SAEs, change in physical exam results and vital signs, laboratory tests and ECG, C-SSRS, BARS and AIMS, CSFQ, and DESS will be assessed as a measure of safety and tolerability [ Time Frame: At all visits during the whole study period. Unsolicited SAEs will be collected for 30 days post last study treatment. ] [ Designated as safety issue: Yes ]
Complete list of historical versions of study NCT01152554 on ClinicalTrials.gov Archive Site
  • Sustained Efficacy at 3 Months, Defined as a Montgomery-Asberg Depression Rating Scale (MADRS) Total Score of ≤12 at Week 12 and All Visits up to and Including Week 24 [ Time Frame: Week 12 to Week 24 ] [ Designated as safety issue: No ]

    The percentage of patients with a a MADRS total score of ≤12 at Week 12 and all visits up to and including Week 24 was calculated. One intermediate occurrence of a MADRS total score >12 but ≤16 or missing was allowed from Week 16 to Week 20.

    A 10-item scale for the evaluation of depressive symptoms. Each MADRS item is rated on a 0 to 6 scale. The MADRS total score is calculated as the sum of the 10 individual item scores; the total score can range from 0 to 60. Higher MADRS scores indicate higher levels of depressive symptoms.

  • Sustained Efficacy at 9 Months, Defined as a MADRS Total Score of ≤12 at Week 12 and at All Visits up to and Including Week 52 [ Time Frame: Week 12 to Week 52 ] [ Designated as safety issue: No ]

    The percentage of patients with a MADRS total score of ≤12 at Week 12 and at all visits up to and including Week 52 was calculated. Two intermediate occurrences (not consecutive) of a MADRS >12 but ≤16 or missing were allowed from Week 16 to Week 48.

    A 10-item scale for the evaluation of depressive symptoms. Each MADRS item is rated on a 0 to 6 scale. The MADRS total score is calculated as the sum of the 10 individual item scores; the total score can range from 0 to 60. Higher MADRS scores indicate higher levels of depressive symptoms.

  • Change in the Clinician-rated Global Outcome of Severity as Measured by the Clinical Global Impression-Severity (CGI-S) Score From Randomization (Week 0) to End of Treatment (Week 52) [ Time Frame: Randomization (Week 0) to end of treatment (Week 52) ] [ Designated as safety issue: No ]
    A 3-part, clinician-administered scale that rates the improvement or worsening of the patient's illness from randomization (baseline). Each item is scored on a 1 to 7 scale. Higher CGI-S scores indicate greater illness severity.
  • Change in Functional Impairment From Randomization (Week 0) to End of Treatment (Week 52) as Measured by the Sheehan Disability Scale (SDS) Total Score [ Time Frame: Randomization (Week 0) to end of treatment (Week 52) ] [ Designated as safety issue: No ]
    Sheehan Disability Scale (SDS) is 5-item, self-administered scale that measures the extent a patient is impaired by their disease. Higher scores indicate more severe impairment. The SDS total score is calculated as the sum of the score for the 3 inter-correlated domains (school/work, social life, and family life/home responsibilities) and ranges from 0 (unimpaired) to 30 (highly impaired).
  • Change in Overall Quality of Life and Satisfaction From Randomization (Week 0) to End of Treatment (Week 52) by Assessing the Quality of Life Enjoyment and Satisfaction Questionnaire-Short Form (Q-LES-Q-SF) % Maximum Total Score [ Time Frame: Randomization (Week 0) to end of treatment (Week 52) ] [ Designated as safety issue: No ]
    The Q-LES-Q-SF total score is derived by summing item scores 1 to 14. Higher scores are indicative of greater enjoyment or satisfaction in each domain. The Q-LES-Q-SF % maximum total score is calculated as 100% × (Q-LES-Q-SF total score - 14) / 56, and can range from 0% to 100%.
  • Change in EuroQol - 5 Dimensions (EQ-5D) From Randomization (Week 0) to End of Treatment (Week 52) [ Time Frame: Randomization (Week 0) to end of treatment (Week 52) ] [ Designated as safety issue: No ]
    A self-assessment questionnaire that provides 2 measures of health status. The EQ-5D index score is a weighted linear combination over 5 dimensions of health status. The score for each of the 5 dimensions can range from 1 to 3, and an equation is used to calculate the EQ-5D index score. The EQ-5D index score can range from possible negative values to a maximum of 1.0. The EQ-VAS is a visual analog scale with a range of 0 to 100. For both variables, a higher score indicates a better health state.
  • To evaluate efficacy of TC-5214 by assessing Montgomery-Åsberg Depression Rating Scale (MADRS) and Clinical Global Impression-Severity (CGI-S) scores. [ Time Frame: MADRS will be measured at visits 1, 3, 4, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17 and 20. CGI-S will be measured at visits 1, 2, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17 and 20. ] [ Designated as safety issue: No ]
  • To evaluate efficacy of TC-5214 by assessing Sheehan Disability Scale, Quality of Life Enjoyment and Satisfaction Questionnaire-Short-Form, European Quality of Life VAS and 5 dimensions and Healthcare resource utilization and work absence scores [ Time Frame: SDS and Q-LES-Q-SF will be measured at visits 1, 7, 10, 13 and 17. EQ-5D and HRUWA will be measured at visits 1, 4, 6 - 17. ] [ Designated as safety issue: No ]
Not Provided
Not Provided
 
A Study to Assess the Long- Term Safety of TC-5214 as an Adjunct Therapy in Patients With Major Depressive Disorder
A Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled, Phase III, Long-Term Safety and Tolerability Study of TC-5214 (S-mecamylamine) as an Adjunct to an Antidepressant in Patients With Major Depressive Disorder Who Exhibit an Inadequate Response to Antidepressant Therapy

The purpose of this study is to determine if TC-5214 or placebo (a tablet that looks like medicine tablet or capsule, but contains no active medicine) is safe and effective when taken for 52 weeks with another antidepressant medicine.

Not Provided
Interventional
Phase 3
Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
  • Major Depressive Disorder
  • MDD
  • Depression
  • Drug: TC-5214
    Tablet, oral, twice daily for 52 weeks
  • Drug: Placebo
    Tablet, oral, twice daily for 52 weeks
  • Experimental: SSRI/Serotonin/SNRI + TC-5214 1-4 mg
    Selective serotonin reuptake inhibitor (SSRI)/Serotonin/norepinephrine reuptake inhibitor (SNRI) + TC-5214 1-4 mg BID
    Intervention: Drug: TC-5214
  • Placebo Comparator: SSRI/Serotonin/SNRI + placebo
    Selective serotonin reuptake inhibitor (SSRI)/Serotonin/norepinephrine reuptake inhibitor (SNRI) + placebo BID
    Intervention: Drug: Placebo
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
813
February 2012
February 2012   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Provision of signed and dated informed consent before initiation of any study-related procedures.
  • The patient must have a clinical diagnosis of major depressive disorder (MDD) with inadequate response to no more than one antidepressant.
  • Outpatient status at enrollment and randomization.

Exclusion Criteria:

  • Patients with a lifetime history of bipolar disorder, psychotic disorder or post-traumatic stress disorder.
  • Patients with a history of suicide attempts in the past year and/or seen by the investigator as having a significant history of risk of suicide or homicide.
  • Patients with significant liver, kidney, lung, heart, neurological, or any other medical conditions that might confound the study or put the patient at greater risk during study participation.
Both
18 Years to 65 Years
No
Contact information is only displayed when the study is recruiting subjects
United States,   Puerto Rico
 
NCT01152554
D4130C00007
No
AstraZeneca
AstraZeneca
Targacept Inc.
Study Director: Hans A. Eriksson, MD, Ph.D, MBA AstraZeneca
Principal Investigator: Andrew . J Cutler, MD Florida Clinical Research Center, LLC
AstraZeneca
March 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP